Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
4.990
-0.100 (-1.96%)
At close: Nov 20, 2026, 4:00 PM EST
5.09
+0.10 (2.00%)
After-hours: Nov 20, 2026, 7:30 PM EST
AVR Revenue
Anteris Technologies Global had revenue of $519.00K in the quarter ending September 30, 2026, with 20.98% growth. This brings the company's total for the last twelve months to $2.33M, up 9.02% year-over-year. In the year 2025, Anteris Technologies Global had annual revenue of $1.91M, down -29.23%. That makes Anteris Technologies Global the 42,108th largest company in the world by revenue and 5,710th in the United States.
Revenue (ttm)
$2.33M
Revenue Growth
+9.02%
P/S Ratio
208.62
Revenue / Employee
$13,402
Employees
174
Market Cap
486.49M
Revenue by Geography
- United States 1.61M 84.1%
- Germany 272.00K 14.2%
- Australia 33.00K 1.7%
Fiscal year ended Dec 31, 2025 See the full AVR breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.91M | -790.00K | -29.23% |
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.59B |
| Tactile Systems Technology | 356.42M |
| Cerus | 226.57M |
| Pacific Biosciences of California | 161.39M |
| Delcath Systems | 109.96M |
| Sight Sciences | 88.40M |
| AVITA Medical | 84.68M |
| BrainsWay | 65.33M |
AVR News
- 5 days ago - Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients - GlobeNewsWire
- 8 days ago - Anteris Technologies price target lowered to $9 from $10 at Barclays - TheFly
- 11 days ago - Anteris Technologies Announces Results for the Third Quarter of 2026 - GlobeNewsWire
- 20 days ago - Anteris Technologies announces 30-day outcomes for medium-size DurAVR THV - TheFly
- 20 days ago - Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026 - GlobeNewsWire
- 25 days ago - Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 - GlobeNewsWire
- 4 weeks ago - Anteris Technologies gets full clearance from German BfArM for DurAVR THV - TheFly
- 4 weeks ago - Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance - GlobeNewsWire